🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to scientists.

An International Health Concern

Gonorrhoea infections are escalating globally, with data suggesting more than 82 million instances per year. Particularly high rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in recent days for use against gonorrhoea. This disease can lead to significant complications, including infertility. Scientists hope that specific application of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This medication, which is additionally indicated for UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This approval signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Outcomes and Global Access

As per data released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The study enrolled nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to register and commercialise the drug in many developing nations.

Medical professionals on the front lines have voiced optimism. Access to a single-dose, oral treatment of this kind is seen as a "game-changer" for gonorrhoea control. This is deemed essential to reduce the burden of the illness for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.